Changes

Volunteer Assignments and Opportunities (view source)

Revision as of 13:05, 7 August 2020

578 bytes added , 13:05, 7 August 2020

no edit summary

Line 4: Line 4:

|-

!'''Disease'''!!'''Page Type'''!!'''Author'''

−

!'''Date Assigned (Target ~~Page~~ Completion Date)'''!!'''Associate Editor'''

+

!'''Date Assigned to Author (Target Completion Date)'''!!'''Associate Editor'''

−

!Author Content Pending or Complete (Date Completed)

+

!'''Author Content Pending or Complete (Date Completed)'''

−

!Editor Reviewed (Date)

+

!'''Date Completed by Author'''

−

!Notes

+

!'''Editor Reviewed (Date of Last Review)'''

+

!'''Notes'''

|-

|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera

Line 13: Line 14:

|Fabiola Quintero-Rivera (FQR)

|PENDING

+

|

Line 21: Line 23:

|FQR

|Complete

+

|

Line 29: Line 32:

|FQR

|PENDING

+

|

Line 37: Line 41:

|FQR

|PENDING

+

|

Line 45: Line 50:

|FQR

|PENDING

+

|

Line 53: Line 59:

|FQR

|PENDING

+

|

Line 61: Line 68:

|FQR

|PENDING

+

|

Line 69: Line 77:

|FQR

|PENDING

+

|

Line 74: Line 83:

|'''''Mastocytosis'''''||'''''Overview'''''||

| ||FQR

+

|

Line 83: Line 93:

|FQR

|PENDING

+

|

Line 91: Line 102:

|FQR

|PENDING

+

|

Line 99: Line 111:

|FQR

|PENDING

+

|

Line 106: Line 119:

|FQR

|PENDING

+

|

Line 113: Line 127:

|FQR

|Complete

+

|

Line 120: Line 135:

|FQR

|Complete

+

|

Line 127: Line 143:

|FQR

|Complete

+

|

Line 134: Line 151:

|FQR

|Complete

+

|

Line 143: Line 161:

|FQR

|Complete

+

|

|NON-WHO ENTITY

Line 152: Line 171:

|FQR

|Complete

+

|

|NON-WHO ENTITY

Line 159: Line 179:

|FQR

|Complete

+

|

Line 166: Line 187:

|FQR

|Complete

+

|

Line 173: Line 195:

|FQR

|Complete

+

|

Line 180: Line 203:

|FQR

|PENDING

+

|

Line 187: Line 211:

|FQR

|PENDING

+

|

Line 194: Line 219:

|FQR

|PENDING

+

|

Line 200: Line 226:

|

|FQR

+

|

Line 208: Line 235:

|FQR

|PENDING

+

|

Line 215: Line 243:

|FQR

|Complete

+

|

Line 222: Line 251:

|FQR

|Complete

+

|

Line 229: Line 259:

|FQR

|PENDING

+

|

Line 236: Line 267:

|FQR

|PENDING

+

|

Line 243: Line 275:

|FQR

|Complete

+

|

Line 250: Line 283:

|FQR

|PENDING

+

|

Line 257: Line 291:

|FQR

|PENDING

+

|

Line 262: Line 297:

| || ||

| ||

+

|

Line 270: Line 306:

|Jennelle Hodge (JH)/ Malini Sathanoori (MS)

|Complete

+

|

Line 276: Line 313:

| ||JH / MS

|Complete

+

|

Line 282: Line 320:

| ||JH / MS

|PENDING

+

|

Line 288: Line 327:

| ||JH / MS

|PENDING

+

|

Line 294: Line 334:

| ||JH / MS

|PENDING

+

|

Line 300: Line 341:

| ||JH / MS

|PENDING

+

|

Line 306: Line 348:

| ||JH / MS

|Complete

+

|

Line 312: Line 355:

| ||JH / MS

|Complete

+

|

Line 319: Line 363:

|JH / MS

|Complete

+

|

Line 325: Line 370:

| ||JH / MS

|Complete

+

|

Line 331: Line 377:

| ||JH / MS

|Complete

+

|

Line 337: Line 384:

| ||JH / MS

|Complete

+

|

Line 343: Line 391:

| ||JH / MS

|Complete

+

|

Line 349: Line 398:

| ||JH / MS

|Complete

+

|

Line 355: Line 405:

| ||JH / MS

|Complete

+

|

|Need permission for figure? Update WHO?

Line 361: Line 412:

| ||JH / MS

|Complete

+

|

Line 367: Line 419:

| ||JH / MS

|Complete

+

|

Line 373: Line 426:

| ||JH / MS

|Complete

+

|

|Add WHO reference

Line 379: Line 433:

| ||JH / MS

|Complete

+

|

Line 385: Line 440:

| ||JH / MS

|Complete

+

|

Line 391: Line 447:

| ||JH / MS

|Complete

+

|

Line 397: Line 454:

| ||JH / MS

|Complete

+

|

|Check reference format

Line 403: Line 461:

| ||JH / MS

|Complete

+

|

Line 409: Line 468:

| ||JH / MS

|Complete

+

|

Line 415: Line 475:

| ||JH / MS

|Complete

+

|

Line 421: Line 482:

| ||JH / MS

|Complete

+

|

Line 427: Line 489:

| ||JH / MS

|Complete

+

|

Line 433: Line 496:

| ||JH / MS

|Complete

+

|

Line 439: Line 503:

| ||JH / MS

|Complete

+

|

Line 445: Line 510:

| ||JH / MS

|Complete

+

|

Line 451: Line 517:

| ||JH / MS

|Complete

+

|

Line 457: Line 524:

| ||JH / MS

|Complete

+

|

Line 463: Line 531:

| ||JH / MS

|Complete

+

|

Line 469: Line 538:

| ||JH / MS

|Complete

+

|

|Need permission for figure?

Line 475: Line 545:

| ||JH / MS

|Complete

+

|

Line 481: Line 552:

| ||JH / MS

|Complete

+

|

Line 487: Line 559:

| ||JH / MS

|Complete

+

|

Line 493: Line 566:

| ||JH / MS

|Complete

+

|

Line 499: Line 573:

| ||JH / MS

|Complete

+

|

|Check reference format

Line 505: Line 580:

| ||JH / MS

|Complete

+

|

Line 511: Line 587:

| ||JH / MS

|Complete

+

|

Line 517: Line 594:

| ||JH / MS

|Complete

+

|

|Check reference format

Line 523: Line 601:

| ||JH / MS

|Complete

+

|

Line 529: Line 608:

| ||JH / MS

|??

+

|

Line 535: Line 615:

| ||JH / MS

|??

+

|

Line 544: Line 625:

|JH / MS

|Complete

+

|

|NON-WHO ENTITY

Line 553: Line 635:

|JH / MS

|PENDING

+

|

|NON-WHO ENTITY

Line 562: Line 645:

|JH / MS

|PENDING

+

|

|NON-WHO ENTITY

Line 567: Line 651:

| || ||

| ||

+

|

Line 573: Line 658:

|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||

| ||Yassmine Akkari (YA)

+

|

Line 579: Line 665:

|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''||

| ||YA

+

|

Line 585: Line 672:

| B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease||

| ||YA

+

|

Line 593: Line 681:

|YA

|PENDING

+

|

Line 598: Line 687:

| B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||

| ||YA

+

|

Line 604: Line 694:

| B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease||

| ||YA

+

|

Line 614: Line 705:

|YA

|Complete

+

|

Line 619: Line 711:

| B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease||

| ||YA

+

|

Line 625: Line 718:

| B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease||

| ||YA

+

|

Line 633: Line 727:

|YA

|Complete

+

|

Line 638: Line 733:

| B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease||

| ||YA

+

|

Line 644: Line 740:

| B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease||

| ||YA

+

|

Line 650: Line 747:

|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||

| ||YA

+

|

Line 656: Line 754:

|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||

| ||YA

+

|

Line 662: Line 761:

|NK-Lymphoblastic Leukemia/Lymphoma||Disease||

| ||YA

+

|

Line 672: Line 772:

|YA

|PENDING

+

|

|NON-WHO ENTITY

Line 677: Line 778:

| || ||

| ||

+

|

Line 683: Line 785:

|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||

| ||Snehal Patel (SP)

+

|

Line 691: Line 794:

|SP

|PENDING

+

|

Line 698: Line 802:

|SP

|PENDING

+

|

Line 705: Line 810:

|SP

|PENDING

+

|

Line 712: Line 818:

|SP

|Complete

+

|

|Malini to review

Line 719: Line 826:

|SP

|Complete

+

|

|Malini to review

Line 726: Line 834:

|SP

|Complete

+

|

|Malini to review

Line 733: Line 842:

|SP

|Complete

+

|

|Malini to review

Line 740: Line 850:

|SP

|Complete

+

|

|Malini to review

Line 747: Line 858:

|SP

|PENDING

+

|

Line 754: Line 866:

|SP

|PENDING

+

|

Line 759: Line 872:

|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||

| ||SP

+

|

Line 765: Line 879:

|'''''Heavy Chain Diseases'''''||'''''Overview'''''||

| ||SP

+

|

Line 771: Line 886:

| Mu Heavy Chain Disease||Disease||

| ||SP

+

|

Line 777: Line 893:

| Gamma Heavy Chain Disease||Disease||

| ||SP

+

|

Line 783: Line 900:

| Alpha Heavy Chain Disease||Disease||

| ||SP

+

|

Line 791: Line 909:

|SP

|PENDING

+

|

Line 798: Line 917:

|SP

|PENDING

+

|

Line 805: Line 925:

|SP

|PENDING

+

|

Line 812: Line 933:

|SP

|PENDING

+

|

Line 819: Line 941:

|SP

|PENDING

+

|

Line 824: Line 947:

|''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||

| ||SP

+

|

Line 830: Line 954:

| Primary Amyloidosis||Disease||

| ||SP

+

|

Line 836: Line 961:

| Light Chain and Heavy Chain Deposition Disease||Disease||

| ||SP

+

|

Line 842: Line 968:

|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||

| ||SP

+

|

Line 848: Line 975:

| POEMS Syndrome||Disease||

| ||SP

+

|

Line 854: Line 982:

| TEMPI Syndrome||Disease||

| ||SP

+

|

Line 862: Line 991:

|SP

|PENDING

+

|

Line 867: Line 997:

|Nodal Marginal Zone Lymphoma||Disease||

| ||SP

+

|

Line 875: Line 1,006:

|SP

|PENDING

+

|

Line 882: Line 1,014:

|SP

|PENDING

+

|

Line 889: Line 1,022:

|SP

|PENDING

+

|

Line 896: Line 1,030:

|SP

|PENDING

+

|

Line 903: Line 1,038:

|SP

|PENDING

+

|

Line 910: Line 1,046:

|SP

|PENDING

+

|

Line 915: Line 1,052:

|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||

| ||SP

+

|

Line 921: Line 1,059:

|Primary Cutaneous Follicle Centre Lymphoma||Disease||

| ||SP

+

|

Line 929: Line 1,068:

|SP

|PENDING - due 8/15/20

+

|

Line 936: Line 1,076:

|SP

|PENDING - due 8/31/20

+

|

Line 943: Line 1,084:

|SP

|PENDING - due 8/15/20

+

|

Line 948: Line 1,090:

| || ||

| ||

+

|

Line 956: Line 1,099:

|Greg Corboy (GC)

|PENDING

+

|

Line 961: Line 1,105:

|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||

| ||GC

+

|

Line 967: Line 1,112:

|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||

| ||GC

+

|

Line 973: Line 1,119:

|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||

| ||GC

+

|

Line 979: Line 1,126:

|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||

| ||GC

+

|

Line 985: Line 1,133:

|EBV-Positive Mucocutaneous Ulcer||Disease||

| ||GC

+

|

Line 991: Line 1,140:

|Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease||

| ||GC

+

|

Line 997: Line 1,147:

| Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease||

| ||GC

+

|

Line 1,003: Line 1,154:

|Lymphomatoid Granulomatosis||Disease||

| ||GC

+

|

Line 1,009: Line 1,161:

|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||

| ||GC

+

|

Line 1,015: Line 1,168:

|Intravascular Large B-cell Lymphoma||Disease||

| ||GC

+

|

Line 1,021: Line 1,175:

|ALK-Positive Large B-cell Lymphoma||Disease||

| ||GC

+

|

Line 1,028: Line 1,183:

| ||GC

|Complete

+

|

Line 1,033: Line 1,189:

|Primary Effusion Lymphoma||Disease||

| ||GC

+

|

Line 1,039: Line 1,196:

|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||

| ||GC

+

|

Line 1,045: Line 1,203:

| Multicentric Castleman Disease||Disease||

| ||GC

+

|

Line 1,051: Line 1,210:

| HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||

| ||GC

+

|

Line 1,057: Line 1,217:

| HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease||

| ||GC

+

|

Line 1,063: Line 1,224:

|Burkitt Lymphoma||Disease||

| ||GC

+

|

Line 1,069: Line 1,231:

|Burkitt-Like Lymphoma with 11q Aberration||Disease||

| ||GC

+

|

Line 1,075: Line 1,238:

|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||

| ||GC

+

|

Line 1,081: Line 1,245:

| High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||

| ||GC

+

|

Line 1,087: Line 1,252:

| High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||

| ||GC

+

|

Line 1,093: Line 1,259:

|B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||

| ||GC

+

|

Line 1,099: Line 1,266:

| || ||

| ||

+

|

Line 1,105: Line 1,273:

|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||

| ||Snehal Patel (SP)

+

|

Line 1,112: Line 1,281:

| ||SP

|PENDING

+

|

Line 1,118: Line 1,288:

| ||SP

|PENDING

+

|

Line 1,124: Line 1,295:

| ||SP

|PENDING

+

|

Line 1,129: Line 1,301:

|Aggressive NK-cell Leukemia||Disease||

| ||SP

+

|

Line 1,135: Line 1,308:

|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''||

| ||SP

+

|

Line 1,141: Line 1,315:

| Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease||

| ||SP

+

|

Line 1,147: Line 1,322:

| Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease||

| ||SP

+

|

Line 1,153: Line 1,329:

| Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||

| ||SP

+

|

Line 1,159: Line 1,336:

| Severe Mosquito Bite Allergy||Disease||

| ||SP

+

|

Line 1,165: Line 1,343:

|Adult T-cell Leukemia/Lymphoma||Disease||

| ||SP

+

|

Line 1,171: Line 1,350:

|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||

| ||SP

+

|

Line 1,179: Line 1,359:

|SP

|PENDING

+

|

Line 1,186: Line 1,367:

|SP

|PENDING

+

|

Line 1,193: Line 1,375:

|SP

|PENDING

+

|

Line 1,200: Line 1,383:

|SP

|PENDING

+

|

Line 1,207: Line 1,391:

|SP

|PENDING

+

|

Line 1,213: Line 1,398:

| ||SP

|PENDING

+

|

Line 1,218: Line 1,404:

|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||

| ||SP

+

|

Line 1,224: Line 1,411:

|Mycosis Fungoides||Disease||

| ||SP

+

|

Line 1,230: Line 1,418:

|Sézary Syndrome||Disease||

| ||SP

+

|

Line 1,236: Line 1,425:

|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''||

| ||SP

+

|

Line 1,242: Line 1,432:

| Lymphomatoid Papulosis||Disease||

| ||SP

+

|

Line 1,248: Line 1,439:

| Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||

| ||SP

+

|

Line 1,254: Line 1,446:

|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||

| ||SP

+

|

Line 1,260: Line 1,453:

| Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||

| ||SP

+

|

Line 1,266: Line 1,460:

| Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||

| ||SP

+

|

Line 1,272: Line 1,467:

| Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||

| ||SP

+

|

Line 1,278: Line 1,474:

| Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||

| ||SP

+

|

Line 1,284: Line 1,481:

|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||

| ||SP

+

|

Line 1,290: Line 1,488:

|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''||

| ||SP

+

|

Line 1,298: Line 1,497:

|SP

|PENDING

+

|

Line 1,305: Line 1,505:

|SP

|PENDING

+

|

Line 1,310: Line 1,511:

| Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease||

| ||SP

+

|

Line 1,318: Line 1,520:

|SP

|PENDING

+

|

Line 1,325: Line 1,528:

|SP

|PENDING

+

|

Line 1,332: Line 1,536:

|SP

|PENDING

+

|

Line 1,337: Line 1,542:

| || ||

| ||

+

|

Line 1,343: Line 1,549:

|'''''Hodgkin Lymphomas'''''||'''''Overview'''''||

| ||Associate Editor??

+

|

Line 1,349: Line 1,556:

|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||

| ||

+

|

Line 1,355: Line 1,563:

|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||

| ||

+

|

Line 1,361: Line 1,570:

| Nodular Sclerosis Classic Hodgkin Lymphoma||Disease||

| ||

+

|

Line 1,367: Line 1,577:

| Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||

| ||

+

|

Line 1,373: Line 1,584:

| Mixed Cellularity Classic Hodgkin Lymphoma||Disease||

| ||

+

|

Line 1,379: Line 1,591:

| Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease||

| ||

+

|

Line 1,385: Line 1,598:

|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||

| ||

+

|

Line 1,391: Line 1,605:

|Lymphomas Associated with HIV Infection||Disease||

| ||

+

|

Line 1,397: Line 1,612:

|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||

| ||

+

|

Line 1,403: Line 1,619:

| Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease||

| ||

+

|

Line 1,413: Line 1,630:

|

|PENDING

+

|

Line 1,418: Line 1,636:

|''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||

| ||

+

|

Line 1,424: Line 1,643:

| Monomorphic B-cell PTLD||Disease||

| ||

+

|

Line 1,430: Line 1,650:

| Monomorphic T/NK-cell PTLD||Disease||

| ||

+

|

Line 1,436: Line 1,657:

| Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||

| ||

+

|

Line 1,442: Line 1,664:

|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease||

| ||

+

|

Line 1,448: Line 1,671:

|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||

| ||

+

|

Line 1,454: Line 1,678:

|Histiocytic Sarcoma||Disease||

| ||

+

|

Line 1,460: Line 1,685:

|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||

| ||

+

|

Line 1,466: Line 1,692:

| Langerhans Cell Histiocytosis||Disease||

| ||

+

|

Line 1,472: Line 1,699:

| Langerhans Cell Sarcoma||Disease||

| ||

+

|

Line 1,478: Line 1,706:

|Indeterminate Dendritic Cell Tumour||Disease||

| ||

+

|

Line 1,484: Line 1,713:

|Interdigitating Dendritic Cell Sarcoma||Disease||

| ||

+

|

Line 1,490: Line 1,720:

|Follicular Dendritic Cell Sarcoma||Disease||

| ||

+

|

Line 1,496: Line 1,727:

| Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||

| ||

+

|

Line 1,502: Line 1,734:

|Fibroblastic Reticular Cell Tumor||Disease||

| ||

+

|

Line 1,508: Line 1,741:

|Disseminated Juvenile Xanthogranuloma||Disease||

| ||

+

|

Line 1,514: Line 1,748:

|Erdheim-Chester Disease||Disease||

| ||

+

|

Line 1,520: Line 1,755:

| || ||

| ||

+

|

Line 1,526: Line 1,762:

| || ||

| ||

+

|

Line 1,532: Line 1,769:

| || ||

| ||

+

|

Line 1,538: Line 1,776:

| || ||

| ||

+

|

Line 1,544: Line 1,783:

| || ||

| ||

+

|

Line 1,550: Line 1,790:

| || ||

| ||

+

|

Line 1,556: Line 1,797:

| || ||

| ||

+

|

Line 1,562: Line 1,804:

| || ||

| ||

+

|

Line 1,568: Line 1,811:

| || ||

| ||

+

|

Line 1,574: Line 1,818:

| || ||

| ||

+

|

Line 1,580: Line 1,825:

| || ||

| ||

+

|

Line 1,586: Line 1,832:

| || ||

| ||

+

|

Line 1,592: Line 1,839:

| || ||

| ||

+

|

Line 1,598: Line 1,846:

| || ||

| ||

+

|

Line 1,604: Line 1,853:

| || ||

| ||

+

|

Line 1,610: Line 1,860:

| || ||

| ||

+

|

Line 1,616: Line 1,867:

| || ||

| ||

+

|

Line 1,622: Line 1,874:

| || ||

| ||

+

|

Line 1,628: Line 1,881:

| || ||

| ||

+

|

Line 1,634: Line 1,888:

| || ||

| ||

+

|

Jennelleh

Bureaucrats, Editors, Administrators

3,909

edits